BioCheetah is a Singapore-based Agency for Science Technology and Research, Institute of Molecular Cell Biology (A*STAR, IMCB) spin-off medical diagnostic company with cutting-edge science on cancer biomarker discovery and liquid biopsy immunodiagnostic tests. We develop non-invasive, protein-based immunodiagnostic applications for the diagnosis of urological cancers. Our current flagship product includes professional In-Vitro Diagnostic (IVD) ELISA and Point-of-Care Testing (POCT) that employs a novel multiplex urine-based biomarker panel with high sensitivity and specificity for the diagnosis and monitoring of bladder cancer. BioCheetah is currently building a ISO 13485 pilot manufacturing facility at Launchpad for the purpose of development and manufacturing of its diagnostic products. In addition, clinical trials are underway with hospitals in Singapore and China.
Company Vision & Mission
BioCheetah aims to offer an alternative approach using its novel biomarkers to reduce invasive procedure.
Our early cancer detection technology delivers pain-free biopsy and better patient triage assessment.